Glatiramer Acetate (Copaxone)

A random polymer of L-ALANINE, L-GLUTAMIC ACID, L-LYSINE, and L-TYROSINE that structurally resembles MYELIN BASIC PROTEIN. It is used in the treatment of RELAPSING-REMITTING MULTIPLE SCLEROSIS.

Also Known As:

Networked: 1033 relevant articles (104 outcomes, 199 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Aharoni, Rina: 23 articles (12/2021 - 05/2002)
2.	Arnon, Ruth: 23 articles (12/2021 - 05/2002)
3.	Ziemssen, Tjalf: 16 articles (01/2022 - 11/2002)
4.	Comi, Giancarlo: 15 articles (11/2021 - 11/2002)
5.	Zamvil, Scott S: 14 articles (01/2020 - 09/2002)
6.	Comi, G: 14 articles (01/2015 - 06/2000)
7.	Sela, Michael: 13 articles (01/2020 - 05/2002)
8.	Wolinsky, J S: 13 articles (01/2015 - 01/2000)
9.	Wolinsky, Jerry S: 12 articles (10/2022 - 08/2003)
10.	Trojano, Maria: 12 articles (01/2022 - 01/2007)

Related Diseases

1.	Multiple Sclerosis 08/01/2000 - "This study demonstrates the sustained efficacy of glatiramer acetate in reducing the relapse rate and in slowing the accumulation of disability in patients with relapsing forms of multiple sclerosis. " 07/01/2013 - "The placebo-controlled phase of the PreCISe study showed that glatiramer acetate delayed onset of clinically definite multiple sclerosis (CDMS) in patients with clinically isolated syndrome and brain lesions on MRI. " 01/01/2010 - "A study included 158 patients stratified into 3 groups: 57 patients with multiple sclerosis (MS) of the main group who were treated with copaxone in dosage 20 mg/d during 4,3±2,6 years, 49 patients without MS with different neurological diseases of the control group and 52 patients diagnosed with "confirmed MS" in the remission stage who were not treated with disease-modifying drugs. " 08/01/2003 - "Three randomized, double-blind, placebo-controlled trials have shown that glatiramer acetate (GA) is effective in reducing relapse rate in patients with relapsing-remitting (RR) multiple sclerosis (MS). " 10/01/2019 - "Glatiramer acetate as a clinically and cost-effective treatment of relapsing multiple sclerosis over 10 years of use within the National Health Service: Final results from the UK Risk Sharing Scheme."
2.	Relapsing-Remitting Multiple Sclerosis 09/20/2012 - "In patients with relapsing-remitting multiple sclerosis, BG-12 (at both doses) and glatiramer acetate significantly reduced relapse rates and improved neuroradiologic outcomes relative to placebo. " 05/01/2007 - "Glatiramer acetate (GA) is effective in reducing clinical and magnetic resonance imaging (MRI) activity in relapsing-remitting multiple sclerosis (RRMS). " 02/27/2009 - "The current study was conducted to evaluate the efficacy of glatiramer acetate (GA), an immunomodulatory drug approved for the treatment of relapsing remitting multiple sclerosis, in preventing the death of C57Bl/6J mice infected with Plasmodium berghei ANKA. " 03/20/2007 - "To evaluate the safety, tolerability, and efficacy of glatiramer acetate (GA) 40 mg daily vs the approved 20-mg formulation in relapsing-remitting multiple sclerosis. " 01/01/2018 - "The aim of this study was to evaluate the safety, tolerability, and efficacy of a brand-generic glatiramer acetate product in patients with relapsing-remitting multiple sclerosis over a 12-month period. "
3.	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 12/01/2004 - "Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies." 01/01/2020 - "We examined the effect of glatiramer acetate (GA) on B-cell maturation, differentiation, and antigen presentation in MS and experimental autoimmune encephalomyelitis (EAE). " 04/01/2016 - "[EFFECT OF PROBIOTIC ENTEROCOCCI AND GLATIRAMER ACETATE ON THE SEVERITY OF EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS IN RATS ]." 03/01/2015 - "Glatiramer acetate guards against rapid memory decline during relapsing-remitting experimental autoimmune encephalomyelitis." 02/03/2015 - "S18, the best analog obtained ameliorated symptoms of experimental autoimmune encephalomyelitis at least twice more effectively than glatiramer acetate or J5. "
4.	Disease Progression 10/01/2009 - "Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial." 09/01/2009 - "This evaluation suggests that IFN Beta-1a SC injection, IFN Beta-1b SC injection, and glatiramer acetate represent the most cost-effective DMDs for the treatment of RRMS, where cost-effectiveness is defined as cost per relapse avoided, assuming that (a) the RRR in relapses and disease progression steps calculated from multiple DMD placebo-controlled clinical trials reflect real differences among DMDs over 2 years; and (b) resource unit costs derived from published sources reflect economic consequences of relapses and disease progression." 05/12/2010 - "Glatiramer acetate did show a partial efficacy in RR MS in term of relapse -related clinical outcomes, without any significant effect on clinical progression of disease measured as sustained disability. " 10/01/2008 - "Glatiramer acetate treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model." 11/01/2005 - "The disease-modifying treatments, IFN-beta and glatiramer acetate, have been widely available over the last decade and have shown a beneficial effect on relapse rate and magnetic resonance imaging parameters of disease activity; however, their effect on disease progression and disability is modest. "
5.	Inflammation (Inflammations) 06/01/2012 - "The results are consistent with a reduction in inflammation due to treatment with glatiramer acetate, though a larger controlled study would be required to prove that association. " 08/25/2010 - "Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE." 06/01/2005 - "We found a significant reduction in the expression of the T(H)1 inflammation associated with the CKRs CXCR3, CXCR6, and CCR5 on glatiramer- and myelin-reactive T cells generated from patients with MS receiving glatiramer therapy vs baseline. " 09/13/2023 - "Oral GlcNAc inhibits inflammation and neurodegeneration markers in MS patients despite concurrent immunomodulation by glatiramer acetate. " 03/01/2006 - "This study assessed whether two doses of glatiramer acetate given orally could improve clinical and MRI measures of inflammation and neurodegeneration in a large cohort of patients with relapsing-remitting multiple sclerosis. "

Related Drugs and Biologics

1.	Glatiramer Acetate (Copaxone)
2.	Interferon-beta
3.	Interferons
4.	Mitoxantrone (Novantrone)
5.	Natalizumab (Tysabri)
6.	Amino Acids
7.	Interferon beta-1b (Betaseron)
8.	Fingolimod Hydrochloride (FTY720)
9.	Proteins (Proteins, Gene)
10.	Peptides (Polypeptides)

Related Therapies and Procedures

1.	Therapeutics
2.	Immunomodulation
3.	Injections
4.	Immunotherapy
5.	Lasers (Laser)